- Home
- MCR vs CERS Comparison
MCR vs CERS Comparison
Compare MCR & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCR
- CERS
- Stock Information
- Founded
- MCR 1989
- CERS 1991
- Country
- MCR United States
- CERS United States
- Employees
- MCR N/A
- CERS N/A
- Industry
- MCR Trusts Except Educational Religious and Charitable
- CERS EDP Services
- Sector
- MCR Finance
- CERS Technology
- Exchange
- MCR Nasdaq
- CERS Nasdaq
- Market Cap
- MCR 265.5M
- CERS 277.2M
- IPO Year
- MCR N/A
- CERS 1997
- Fundamental
- Price
- MCR $6.30
- CERS $1.36
- Analyst Decision
- MCR
- CERS Strong Buy
- Analyst Count
- MCR 0
- CERS 2
- Target Price
- MCR N/A
- CERS $3.50
- AVG Volume (30 Days)
- MCR 66.7K
- CERS 1.1M
- Earning Date
- MCR 01-01-0001
- CERS 07-31-2025
- Dividend Yield
- MCR 8.52%
- CERS N/A
- EPS Growth
- MCR N/A
- CERS N/A
- EPS
- MCR 0.38
- CERS N/A
- Revenue
- MCR N/A
- CERS $185,144,000.00
- Revenue This Year
- MCR N/A
- CERS $20.97
- Revenue Next Year
- MCR N/A
- CERS $15.55
- P/E Ratio
- MCR $16.61
- CERS N/A
- Revenue Growth
- MCR N/A
- CERS 13.06
- 52 Week Low
- MCR $5.63
- CERS $1.12
- 52 Week High
- MCR $6.70
- CERS $2.54
- Technical
- Relative Strength Index (RSI)
- MCR 46.48
- CERS 45.56
- Support Level
- MCR $6.28
- CERS $1.35
- Resistance Level
- MCR $6.33
- CERS $1.47
- Average True Range (ATR)
- MCR 0.04
- CERS 0.07
- MACD
- MCR -0.01
- CERS -0.01
- Stochastic Oscillator
- MCR 24.56
- CERS 2.38
About MCR MFS Charter Income Trust
MFS Charter Income Trust is a United States-based closed-end fund. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests the assets in Debt Instruments, Corporate Bonds, U.S. Government Securities, Foreign Government Securities, Securitized Instruments, Derivatives, Principal Risks, Debt Management Risk, Investment Selection Risk, Interest Rate Risk, Credit Risk, Foreign Risks, Emerging Markets Risk, Currency Risk, Leveraging Risk, Operational and Cybersecurity Risk, Active and Frequent Trading, and etc of different market countries.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.